ERBB2 and breast neoplasm: The effect of lumretuzumab, when combined with pertuzumab and paclitaxel on metastatic breast tumors expressing simultaneously Her2- and Her3, has been investigated in a clinical trial phase I. The results of this study revealed that combination therapy has a narrow therapeutic window to promote further clinical tests [84].